Abstracts Archive - Page 1930 of 2425 - ACR Meeting Abstracts

Abstract Number: 1827 • 2014 ACR/ARHP Annual Meeting
Anti-Ro and Anti-La Antibodies in the General Pregnant Population
Evelyn V. Rozenblyum¹, Sharon Sukhdeo², Edgar Jaeggi³, Lisa Hornberger⁴, Philip Wyatt⁵, Carl A. Laskin⁶ and Earl D. Silverman⁷, ¹Pediatrics, University of Toronto, Toronto, ON, Canada, ²Faculty of Medicine, University of Toronto, Toronto, ON, Canada, ³Cardiology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁴Pediatric Cardiology , Tel: 780-407-3355; Fax: 780-407-3954;, Stollery Children's Hospital, Edmonton, ON, Canada, ⁵Department of Genetics, North York General Hospital, Toronto, ON, Canada, ⁶University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁷Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose Neonatal lupus erythematosus (NLE) is a passively transferred autoimmune disease that occurs in babies born to pregnant women with anti-Ro and anti-La antibodies. The…
Abstract Number: 1846 • 2014 ACR/ARHP Annual Meeting
The Association Between Hydroxychloroquine Treatment and Cardiovascular Morbidity Among Rheumatoid Arthritis Patients
Michael Shapiro¹ and Yair Levy², ¹Haim Lebanon 55, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ²Internal Medicine E, Meir Medical Center, Kfar Saba, Israel
Background/Purpose: Accelerated atherosclerosis and cardiovascular disease are the main causes of mortality in Rheumatoid Arthritis (RA). The anti-malarial drug Hydroxychloroquine (HCQ) has long been used…
Abstract Number: 1845 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Combination Therapy or Monotherapy or Methotrexate Monotherapy in Methotrexate-Naive Patients with Early Rheumatoid Arthritis: 2-Year Clinical and Radiographic Results from a Randomized, Placebo-Controlled Trial
Gerd Burmester¹, William Rigby², Ronald F. van Vollenhoven³, Jonathan Kay⁴, Andrea Rubbert-Roth⁵, Ricardo Blanco⁶, Ariella Kelman⁷, Sophie Dimonaco⁸ and Nina Mitchell⁸, ¹Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Karolinska Institute, Stockholm, Sweden, ⁴UMass Memorial Medical Center, Worcester, MA, ⁵University of Cologne, Cologne, Germany, ⁶Hospital Marques de Valdecilla, Santander, Spain, ⁷Genentech, South San Francisco, CA, ⁸Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: Treatment with tocilizumab (TCZ) in combination with MTX or as monotherapy (Mono) in MTX-naive patients (pts) with early RA resulted in improved signs and…
Abstract Number: 1844 • 2014 ACR/ARHP Annual Meeting
Identification of a Patient Phenotype Which Impacts Response to Therapy in Rheumatoid Arthritis Clinical Trials: Certolizumab Pegol Phase 4 Trial Data
Jeffrey R. Curtis¹, Melvin Churchill², Alan Kivitz³, Laura Gauer⁴, Christopher Herrem⁴, David Carter⁵, Jeffrey Melin⁴ and Yusuf Yazici⁶, ¹The University of Alabama at Birmingham, Birmingham, AL, ²Arthritis Center of Nebraska, Lincoln, NE, ³Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁴UCB Pharma, Smyrna, GA, ⁵UCB Pharma, Brussels, Belgium, ⁶New York University Hospital for Joint Diseases, New York, NY
Background/Purpose The PREDICT trial (NCT01255761) examined predictability of certolizumab pegol (CZP) treatment success at Week (Wk) 52 based on response at Wk12 assessed by RAPID3…
Abstract Number: 1843 • 2014 ACR/ARHP Annual Meeting
Randomised Controlled Non-Inferiority Study of Dose Reduction and Withdrawal of Adalimumab and Etanercept in Rheumatoid Arthritis
Noortje van Herwaarden¹, Aatke van der Maas¹, Michiel Minten¹, Frank H.J. van den Hoogen², Ronald F. van Vollenhoven³, Johannes W.J. Bijlsma⁴, Bart van den Bemt⁵ and Alfons A. den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Rheumatology, Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, ³Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, ⁴Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Pharmacy, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose TNF inhibitors (TNFi) have proven to be effective in the treatment of rheumatoid arthritis (RA). They are however associated with side effects and high…
Abstract Number: 1842 • 2014 ACR/ARHP Annual Meeting
High Rates of Failure after Biological DMARD Discontinuation While in Remission in a Japanese Multi-Center Registry
Kazuki Yoshida^1,2, Mitsumasa Kishimoto³, Helga Radner^1,4, Kazuo Matsui⁵, Masato Okada⁶, Yukihiko Saeki⁷, Daniel H. Solomon¹ and Shigeto Tohma⁸, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Department of Rheumatology, Kameda Medical Center, Kamogawa City, Japan, ³Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁴Department of Internal Medicine III; Division of Rheumatology, Medical University Vienna, Vienna, Austria, ⁵Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, ⁶Division of Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ⁷Department of Clinical Research, Osaka-Minami Medical Center, Osaka, Japan, ⁸Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan
Background/Purpose: Since the introduction of biological disease-modifying antirheumatic drugs (bDMARDs) and tight control strategies, remission has become a more feasible treatment target for an increasing…
Abstract Number: 1841 • 2014 ACR/ARHP Annual Meeting
Eventual Joint Failure and Surgery Rates in Rheumatoid Arthritis Remain High in Patients with Moderate Disease Activity in the First 5 Years of Disease
Elena Nikiphorou¹, Lewis Carpenter², Sam Norton³, Josh Dixey⁴, Patrick Kiely⁵, David Walsh^6,7 and Adam Young^1,8, ¹School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, ²Centre for Lifespan & Chronic Illness Research, University of Hertfordshire, Hatfield, United Kingdom, ³Institute of Psychiatry, King's College London, London, United Kingdom, ⁴Rheumatology, New Cross Hospital, Wolverhampton, United Kingdom, ⁵Rheumatology Dept, St. Georges Healthcare NHS Trust, London, United Kingdom, ⁶Arthritis Research UK Pain Centre, University of Nottingham, Nottingham, United Kingdom, ⁷Rheumatology, Sherwood Forest Hospitals NHS Foundation Trust, Sutton-in-Ashfield, United Kingdom, ⁸Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom
Background/Purpose: It is well-established that sustained high disease activity in RA results in worse outcomes. In reality many patients remain in low/moderate disease activity states,…
Abstract Number: 1840 • 2014 ACR/ARHP Annual Meeting
Pregnancy Outcomes Following Exposure to Abatacept during Pregnancy
M Kumar¹, L Ray¹, S Vemuri² and T Simon¹, ¹Bristol-Myers Squibb, Hopewell, NJ, ²Bristol-Myers Squibb, Plainsboro, NJ
Background/Purpose: Limited data are currently available in the medical literature to guide counseling of patients regarding pregnancy outcomes when treated with abatacept, a selective T-cell…
Abstract Number: 1824 • 2014 ACR/ARHP Annual Meeting
A Randomized Double-Blind Placebo-Controlled Trial of Vitamin D Supplementation in Juvenile-Onset Systemic Lupus Erythematosus: Improvement in Disease Activity and Fatigue Scores
Glauce Lima, Juliane Paupitz, Liliam Takayama, Eloisa Bonfa and Rosa M R Pereira, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose Vitamin D has an important immunomodulatory effect but there are no clinical trials that directly addressed the benefit from boosting the serum level of…
Abstract Number: 1823 • 2014 ACR/ARHP Annual Meeting
Inflammation Is Associated with Erosive Progression in Patients with Hand Osteoarthritis: A Prospective Ultrasonography Study
Marion C. Kortekaas^1,2, Wing Yee Kwok³, Monique Reijnierse⁴, Theo Stijnen⁵ and Margreet Kloppenburg⁶, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Flevoziekenhuis, Almere-Stad, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁵Medical Statistics, Leiden University Medical Center, Leiden, Netherlands, ⁶Rheumatology and Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Erosive hand osteoarthritis (OA) is a subset that shows inflammatory features with ultrasound or MRI much more frequent than non-erosive hand OA, and can…
Abstract Number: 1822 • 2014 ACR/ARHP Annual Meeting
Increasing Synovitis and Bone Marrow Lesions Are Associated with Incident Joint Tenderness in Hand Osteoarthritis
Ida K. Haugen¹, Barbara Slatkowsky-Christensen¹, Pernille Boyesen¹, Sølve Sesseng², Désirée van der Heijde^1,3 and Tore K. Kvien⁴, ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Radiology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Leiden University Medical Ctr, Leiden, Netherlands, ⁴PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose: As hand osteoarthritis (OA) studies with repeated MRI are lacking, longitudinal associations between synovitis and bone marrow lesions (BMLs) and pain are unknown. Our…
Abstract Number: 1821 • 2014 ACR/ARHP Annual Meeting
The Co-Occurrence Patterns of MRI Lesions and Incident Knee Osteoarthritis: The MOST Study
Jingbo Niu¹, David T. Felson², Tuhina Neogi³, Michael C. Nevitt⁴, Cora E. Lewis⁵, James Torner⁶, Ali Guermazi⁷, Frank Roemer⁸ and Yuqing Zhang³, ¹Clinical Epidemiology Research and Training Unit, Boston University, Boston, MA, ²Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA, ³Boston University School of Medicine, Boston, MA, ⁴Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA, ⁵Preventive Medicine, University of Alabama, Birmingham, Birmingham, AL, ⁶Epidemiology, University of Iowa, Iowa City, IA, ⁷Radiology, Boston University School of Medicine, Boston, MA, ⁸Klinikum Augsburg, Augsburg, Germany
Background/Purpose: MRI imaging provides insights of tissue-specific lesions of osteoarthritis (OA) and has the advantage of identifying earlier pathological changes that are not evident on…
Abstract Number: 1820 • 2014 ACR/ARHP Annual Meeting
Discordance of Hip Pain with Radiographic Hip Osteoarthritis: The Osteoarthritis Initiative
Chan Kim¹, Michael C. Nevitt², Pia M. Jungmann³, Irina Tolstykh⁴, Nancy E. Lane⁵, Thomas M. Link⁶ and David T. Felson⁷, ¹Rheumatology, Boston University, Boston, MA, ²Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA, ³Radiology, Technische Universitaet Muenchen, Munich, Germany, ⁴Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁵Internal Medicine, Center for Musculoskeletal Health, UC Davis School of Medicine, Sacramento, CA, ⁶Musculoskeletal Quantitative Imaging Research Group, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, ⁷Arthritis Research UK Centre for Epidemiology, Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom
Background/Purpose It is assumed that persons with hip pain from osteoarthritis (OA) are likely to have radiographic OA, making it possible to readily diagnose disease,…
Abstract Number: 1818 • 2014 ACR/ARHP Annual Meeting
Subchondral Bone Mineral Density Improves Prediction of Knee Osteoarthritis Progression Compared with Clinical Factors Alone: Data from the Osteoarthritis Initiative
Michael P. Lavalley¹, Grace H. Lo², Lori Lyn Price³, Jeffrey Driban⁴, Charles Eaton⁵ and Timothy E. McAlindon⁶, ¹Biostatistics, Boston University, Boston, MA, ²VA HSR&D Center for Innovations in Quality, Effectiveness and Safety; Medical Care Line and Research Care Line; Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, ³Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, ⁴Tufts Medical Center, Boston, MA, ⁵Center for Primary Care and Prevention, Memorial Hospital of Rhode Island, Providence, RI, ⁶Division of Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose A prediction rule for knee osteoarthritis (OA) progression would have great clinical utility in identifying at-risk patients for intervention. Rules using clinically available measurements…
Abstract Number: 1817 • 2014 ACR/ARHP Annual Meeting
Connecting Two Pathways through Ca²⁺ Signaling: NLRP3 Inflammasome Activation Induced By a Hypermorphic PLCG2 Mutation
Jae Jin Chae¹, Yong Hwan Park¹, Chung Park², Il-Young Hwang², Patrycja Hoffmann³, John Kehrl², Ivona Aksentijevich³ and Daniel L. Kastner⁴, ¹Medical Genetics Branch, National Human Genome Research Institute, Bethesda, MD, ²National Institute of Allergy and Infectious Diseases, Bethesda, MD, ³Inflammatory Diseases Section, National Human Genome Research Institute, Bethesda, MD, ⁴Inflammatory Disease Section, National Human Genome Research Institute, Bethesda, MD
Background/Purpose Previously, we reported that a novel variant, p.Ser707Tyr, in phospholipase Cγ2 (PLCγ2) is the cause of a dominantly inherited autoinflammatory disease, APLAID (autoinflammation and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].